BIVI · BioVie Inc.
AI read · Neutral
The AI's read
Higher research costs are adding to BioVie’s loss, and the company still has no sales. Its Parkinson’s study met planned endpoints, and it is preparing a Phase 3 plan for its liver program. These costs and research progress point in different directions, so this report does not change the company’s outlook.